BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20008097)

  • 1. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
    Basu B; Sirohi B; Corrie P
    Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system--therapeutic strategies].
    Auernhammer CJ; Jauch KW; Hoffmann JN
    Zentralbl Chir; 2009 Sep; 134(5):410-7. PubMed ID: 19757340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New perspectives in the treatment of neuroendocrine tumours.
    Bajetta E; Catena L; Valente M; Bianco N; Bellomo F; Bombardieri E
    Anticancer Res; 2012 Oct; 32(10):4193-200. PubMed ID: 23060539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Medical treatment of digestive neuroendocrine tumours].
    Panzuto F; Nasoni S; Delle Fave G
    Minerva Endocrinol; 2001 Sep; 26(3):145-8. PubMed ID: 11753237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of neuroendocrine tumors of the digestive tract].
    Wada I; Shimizu N; Seto Y
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1606-10. PubMed ID: 19838017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
    Desai KK; Khan MS; Toumpanakis C; Caplin ME
    Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
    Srirajaskanthan R; Toumpanakis C; Meyer T; Caplin ME
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1143-54. PubMed ID: 19298583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioguided surgery and systemic radionuclide therapy of neuroendocrine tumours.
    Hodolic M; Fettich J; Marzola MC; Tonini E; Al-Nahhas A; Rubello D
    In Vivo; 2010; 24(1):97-100. PubMed ID: 20133983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New insights into neuroendocrine tumors: molecular biology, imaging and targeted therapies].
    Rohmer V
    Bull Acad Natl Med; 2010 Jan; 194(1):97-104; discussion 104-5. PubMed ID: 20669562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [State of the art and therapeutic prospects in neuroectodermal tumours and other neuroendocrine pathologies].
    Guida T; Belsito Petrizzi V; Fiorentino R; Germano D; Guardasi R; Lentini-Graziano ML; Cartenì G
    Minerva Endocrinol; 2001 Dec; 26(4):215-24. PubMed ID: 11782706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analogs for the treatment of neuroendocrine tumors.
    Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N; Reidy-Lagunes D
    Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
    Lang A; Graeven U
    Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Hobday T; Castellano D; Reidy-Lagunes D; García-Carbonero R; Carrato A
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():19-26. PubMed ID: 21308478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.
    Vilar E; Salazar R; Pérez-García J; Cortes J; Oberg K; Tabernero J
    Endocr Relat Cancer; 2007 Jun; 14(2):221-32. PubMed ID: 17639039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours.
    Khan MS; Caplin ME
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S53-74. PubMed ID: 22005115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
    Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
    Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.